Competing in the European Cancer Diagnostics Market:
France, Germany, Italy, Spain, UK

This new report from Venture Planning Group identifies and evaluates major business opportunities emerging in the cancer diagnostics market during the next five years; examines trends in France, Germany, Italy, Spain, and the UK; reviews current and emerging tests; analyzes potential applications of various diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading market players and potential entrants; and suggests alternative business expansion strategies for suppliers.

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease.  During the next five years, the European cancer diagnostic testing market is promising to be an exciting, dynamic and rapidly expanding field.  Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy.  The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion.

Table of Contents

I.       Introduction

II.      Worldwide Technology and Market Overview

             A.  Cancer Statistics and Etiology

             B.  Major Current and Emerging Cancer Diagnostics Tests

             C.  Instrumentation Review and Market Needs

             D.  Current and Emerging Technologies

III.     France

V.      Italy

VI.     Spain

VIII.    Major Product Development Opportunities

IX.      Alternative Market Penetration Strategies

X.       Design Criteria for Decentralized Testing Products

XI.      Potential Market Entry Barriers and Risks

XII.     Competitive Assessments

XIII.    Appendix